Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update

/PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases,...

Related Keywords

Berwyn ,Pennsylvania ,United States ,Marial Maccecchini ,Maria Maccecchini ,Nic Johnson ,Jeffrey Cummings ,Krista Lanct ,Annovis Bio ,Exchange Commission ,Systems Biology Of Alzheimer Disease Panel ,Movement Disorder Society ,Alzheimer Association International Conference ,Annovis Bio Inc ,Drug Administration ,Russo Partners ,Quarter Highlights ,Buntanetap Phase ,Disorder Society Sponsored Revision ,Unified Parkinson ,Disease Rating Scale ,Participant Global Impression ,Wechsler Adult Intelligence Scale ,Mini Mental State Examination ,First Patient ,Early Parkinson ,Clinical Data ,Novel Translational Inhibitor ,Multiple Neurotoxic Proteins ,Both Alzheimer ,Henry Hagopian ,Chief Financial Officer ,Patents Covering ,Amyloid Lateral Sclerosis ,Prion Diseases ,Association International Conference ,Systems Biology ,Disease Panel ,Association International ,Third Quarter ,Down Syndrome ,Annual Report ,